The Federal Circuit’s refusal to reconsider its ruling forcing Teva to delist asthma-inhaler patents from the FDA’s Orange ...

Teva Pharmaceuticals filed a patent infringement lawsuit against Amneal Pharmaceuticals alleging that their generic version of ...

Late last year we reported on the United States Court of Appeals for the Federal Circuit decision holding that certain device patents should not ...

The FDA has approved the first generic versions of Johnson & Johnson's big-selling anticoagulant Xarelto, which brought in ...

Q4 2024 revenue increased 24.6% over Q3 2024; Full-year 2024 revenue grew 97.8% year-over-yearStrong growth in key commercial metrics, including ...

IPA also stated that while generics are priced lower than the corresponding brands, it is unfair and unacceptable to link quality with cost.

The USFDA has established an office in India to oversee the number of Indian manufacturers qualified to supply generic ...

Evoke Pharma, Inc. ( NASDAQ: EVOK) Q4 2024 Earnings Conference Call March 13, 2025 4:30 PM ET Daniel Kontoh-Boateng – DKB Partners Matt D’Onofrio – Chief Executive Officer Chris Quesenberry – Chief ...

A much-anticipated meeting between President Donald Trump and representatives of the pharmaceutical industry took place ...

Asserting that quality standards are not region-dependent, the Indian Pharmaceutical Alliance (IPA) on Wednesday refuted the ...

VOQUEZNA® (vonoprazan) generated $55.3 million in 2024 net revenues in its first full year of launch, driven by strong demand, including $29.7 ...

Catalyst Pharmaceuticals' Firdapse delivers strong growth with a 37% CAGR. Click here to find out why CPRX stock is a Hold.